Recently published evidence that the world’s first licensed dengue vaccine poses a safety risk to people who have never before been infected with the disease has cast a chill over a critically important but risky field of vaccine development.
Several other dengue vaccines are in the pipeline. But problems with Sanofi Pasteur’s Dengvaxia are now generating questions about the others.
About the Author Reprints
